Business
-
Firebrick Pharma announced that it has launched Nasodine povidone-iodine nasal spray in the US via direct sales through a web site. The company said that it will not make any therapeutic claims so that the… Read more . . .
-
According to Orexo, the United States Patent and Trademark Office (USPTO) has granted US Patent No. 11,957,647 (“Pharmaceutical composition comprising adrenaline”), which covers Orexo’s OX640 epinephrine nasal powder product. The USPTO previously issued US patent… Read more . . .
-
Inhalation CDMO Vectura has partnered with Mundipharma to reformulate Flutiform fluticasone propionate / formoterol fumarate MDI using a lower global warming potential (LGWP) propellant, the companies announced. According to the announcement, the first step in the reformulation… Read more . . .
-
Silo Pharma announced that it will exercise an option for an exclusive worldwide license to develop SPC-14, an intranasal therapy for the treatment of Alzheimer’s disease, from Columbia University. Silo says that it expects the… Read more . . .
-
The Cystic Fibrosis Foundation announced that it making an additional investment of up to $8.5 million to support a Phase 2 trial of SpliSense’s nebulized SPL84 antisense oligonucleotide in patients with cystic fibrosis associated with the… Read more . . .
-
Acorda Therapeutics announced that it has filed to begin Chapter 11 bankruptcy proceedings and said that Merz Therapeutics will serve as a “stalking horse” bidder for Acorda’s assets, including the rights to Inbrija inhaled dry… Read more . . .
-
Launch Therapeutics will take over management of clinical trials of Teva’s TEV-‘248 fluticasone / albuterol (salbutamol) DPI for the treatment of asthma, the companies have announced. In addition, Carlyle Group subsidiary Abingworth, a Launch Therapeutics… Read more . . .
-
The US Federal Trade Commission (FTC) recently filed an amicus brief in a patent infringement case filed by Teva against Amneal after Amneal submitted an ANDA for a generic version of Teva’s ProAir HFA albuterol MDI in… Read more . . .
-
Marinomed Biotech has announced a new agreement with VitaPlus for distribution of one of Marionomed’s Carragelose nasal sprays in Hungary and another agreement with GAIA Healthcare for marketing of two Carragelose nasal sprays in the… Read more . . .
-
AstraZeneca has announced that it will “expand the savings programs for its entire US inhaled respiratory portfolio,” capping costs at $35 per month for “eligible patients” as of June 1, 2024, while noting that “terms… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden